Event-Driven Stocks

BIOMARIN PHARMACEUTICAL INC

BMRNNasdaq

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 6 gooddetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$3.22B$2.85B$2.42B$2.10B$1.85B$1.86B
Operating income$409.5M$484.2M$185.8M$161.0M−$82.3M−$43.4M
Net income$348.9M$426.9M$167.6M$141.6M−$64.1M$854.0M
Total assets$7.59B$6.99B$6.84B$6.38B$6.00B$5.85B
Total liabilities$1.51B$1.33B$1.89B$1.77B$1.74B$1.74B
Equity$6.09B$5.66B$4.95B$4.60B$4.27B$4.10B
EPS (diluted)$1.80$2.21$0.87$0.75$-0.35$4.50
Shares out.190.8M188.7M186.5M184.0M181.8M179.9M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
12.7%
Net margin
10.8%
Return on equity
5.7%
Return on assets
4.6%
Return on capital (ROCE)
6.0%
Liabilities / assets
19.8%
Debt / equity
0.25×
Book value / share
$31.91
Revenue growth (YoY)
12.9%
Net income growth (YoY)
−18.3%

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
7.43safe
Accruals / assets
−6.3%clean
Beneish M-Score
-2.49normal
Piotroski F-Score
4/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
77
/ 100
Profitability 100Growth 50Catalyst 33Earnings quality 100Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 6 good
  • Operating margin is positive
  • Revenue is growing year-over-year
  • Conservative leverage (liabilities < 50% of assets)
  • Positive operating cash flow
  • Clean earnings (low accruals)
  • Altman Z″ in the safe zone

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

FDA-approved drugs

openFDA · most recent
  • NAGLAZYMEMay 31, 2005
  • ALDURAZYMEApr 30, 2003

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 202611.4M5.4+5.3%
Apr 30, 202610.8M7.3+6.3%
Apr 15, 202610.2M6.4+14.9%
Mar 31, 20268.8M4.2+3.9%
Mar 13, 20268.5M4.6+2.9%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (3)